[ad_1]
Some 1,780 Jerusalem residents are employed in the two branches of Teva.
(photo credit: MARC ISRAEL SELLEM)
X
Dear reader,
As you can imagine, more people are reading the Jerusalem Post than ever before.
Nevertheless, traditional economic models are no longer sustainable and quality publications,
like ours, are forced to look for new ways to continue. Unlike many other media outlets,
we have not set up a paywall. We want to keep our journalism open
and accessible and be able to continue to provide you with news
and analyzes of the front lines of Israel, the Middle East and the Jewish world.
As one of our faithful readers, we ask you to be our partner.
For $ 5 per month, you will have access to the following:
- A user experience almost completely devoid of ads
- Access to our Premium section
- Content of the award-winning Jerusalem Report and our monthly magazine to learn Hebrew – Ivrit
- A brand new electronic paper presenting the daily newspaper as it appears in Israel
Help us grow and continue to tell the story of Israel to the world.
Thank you,
Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, editor-in-chief
IMPROVE YOUR JPOST EXPERIENCE OF $ 5 PER MONTH
Show me later
Nov. 27 – Teva Pharmaceutical Industries Ltd is recalling certain combinations of valsartan, a medicine for high blood pressure, as a result of the discovery of an impurity causing cancer, the latest worldwide recall of the drug.
The Israeli drug manufacturer will remember all lots of combined tablets of amlodipine-valsartan and amlodipine-valsartan-hydrochlorothiazide because of an impurity in an ingredient manufactured by a Mylan unit based in India, the FDA announced Tuesday. (Http://bit.ly/2DOBSfu)
The European Union has actually banned last week https://www.reuters.com/article/us-mylan-valsartan-united-states/mylan-recalls-batches-of-blood-pressure-medicine-in- us-idUSKCN1NP2I3 sales of Valsartan manufactured by the Mylan India unit after the discovery of certain batches contained the same impurity, N-nitrosodiethylamine.
Teva has not received any reports of adverse events signaling a potential link or exposure to valsartan, said the health regulator.
Patients are advised to continue taking their medications as the risk of harm may be higher if treatment is discontinued immediately without comparable treatment, the FDA said.
Join Jerusalem Post Premium Plus now for just $ 5 and enhance your experience with an ad-free website and exclusive content. Click here >>
[ad_2]
Source link